Blood products transfused (RBC) % of patients · cardiac surgery for the treatment of non‐surgical bleeding
It is very uncertain whether PCC changes blood products transfused (RBC) % of patients compared with FVIIa (very low certainty).
1 finding from 1 review
All thrombotic events (including myocardial infarction, ischaemic stroke, other arterial thromboembolism, and venous thromboembolism) · cardiac surgery for the treatment of non‐surgical bleeding
It is very uncertain whether PCC changes thrombotic events compared with FVIIa (very low certainty).
1 finding from 1 review
Mortality (30‐day) · cardiac surgery for the treatment of non‐surgical bleeding
It is very uncertain whether PCC changes mortality (30‐day) compared with FVIIa (very low certainty).
1 finding from 1 review
Bleeding (chest drain output) in mLs for the first 12 hours · cardiac surgery for the treatment of non‐surgical bleeding
1 finding from 1 review
Length of critical care stay (hours) · cardiac surgery for the treatment of non‐surgical bleeding
1 finding from 1 review
Incidence of renal impairment · cardiac surgery for the treatment of non‐surgical bleeding
It is very uncertain whether PCC changes incidence of renal impairment compared with FVIIa (very low certainty).
1 finding from 1 review
Adverse events · cardiac surgery for the treatment of non‐surgical bleeding
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Blood products transfused (RBC) % of patients · cardiac surgery for the treatment of non‐surgical bleeding
PCC showed no clear difference in blood products transfused (RBC) % of patients compared with standard treatment (low certainty).
1 finding from 1 review
All thrombotic events (including myocardial infarction, ischaemic stroke, other arterial thromboembolism, and venous thromboembolism) · cardiac surgery for the treatment of non‐surgical bleeding
PCC showed no clear difference in thrombotic events compared with standard treatment (moderate certainty).
1 finding from 1 review
Mortality (30‐day) · cardiac surgery for the treatment of non‐surgical bleeding
PCC showed no clear difference in mortality (30‐day) compared with standard treatment (moderate certainty).
1 finding from 1 review
Length of critical care stay (hours) · cardiac surgery for the treatment of non‐surgical bleeding
1 finding from 1 review
Incidence of renal impairment · cardiac surgery for the treatment of non‐surgical bleeding
PCC showed no clear difference in incidence of renal impairment compared with standard treatment (low certainty).
1 finding from 1 review
Bleeding (chest drain output) in mLs for the first 12 hours · cardiac surgery for the treatment of non‐surgical bleeding
1 finding from 1 review
Adverse events · cardiac surgery for the treatment of non‐surgical bleeding
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Blood products transfused (RBC) in units ‐ intraoperative · cardiac surgery for the treatment of non‐surgical bleeding
1 finding from 1 review
Total VTE · people undergoing bariatric surgery
Heparin started before showed no clear difference in VTE compared with after the surgical procedure (low certainty).
1 finding from 1 review
Major bleeding · people undergoing bariatric surgery
It is very uncertain whether heparin started before changes major bleeding compared with after the surgical procedure (very low certainty).
1 finding from 1 review
All‐cause mortality · people undergoing bariatric surgery
1 finding from 1 review
VTE‐related mortality4 · people undergoing bariatric surgery
1 finding from 1 review
PE · people undergoing bariatric surgery
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found